Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company released its 3Q2025 financial results that showed continued progress toward commercialization of an important pain reliever that we believe is critically needed. Additionally, the company announced new funding to further advance the commercialization process.
